Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

678P - Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI)

Date

16 Sep 2021

Session

ePoster Display

Topics

Immunotherapy

Tumour Site

Renal Cell Cancer

Presenters

Andrew Hahn

Citation

Annals of Oncology (2021) 32 (suppl_5): S678-S724. 10.1016/annonc/annonc675

Authors

A.W. Hahn1, P.V. Viscuse1, A. Pieretti2, A.J. Wiele1, E. Jonasch3, J. Gao3, A.J. Zurita3, A.Y. Shah3, M.T. Campbell3, P. Sharma3, C.G. Wood2, N.M. Tannir3, J.A. Karam2, P. Msaouel3

Author affiliations

  • 1 Cancer Medicine, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Urology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
More

Abstract 678P

Background

Recent clinical data has renewed the debate regarding the role of CN for patients with metastatic RCC (mRCC). Metastatic S/R clear cell RCC is an aggressive variant that responds to ICI. However, the role of CN for metastatic S/R RCC in the ICI era has not been reported to date. Here, we evaluate CN outcomes in patients with metastatic S/R RCC treated with ICI.

Methods

We retrospectively reviewed the records of patients with mRCC with sarcomatoid, rhabdoid, or sarcomatoid plus rhabdoid dedifferentiation who had primary renal tumor in situ and received an ICI-based regimen at MD Anderson Cancer Center. Clinical endpoints of interest were time on ICI therapy and OS from ICI initiation. A directed acyclic graph was used to identify potential confounders to be adjusted in regression models. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated using multivariable Cox regression models.

Results

91 patients with metastatic S/R RCC received an ICI. At ICI initiation, 79.1% of patients had > 1 site of metastases, and 59.3% had International Metastatic RCC Database Consortium (IMDC) intermediate-risk disease. ICI was given as first-line treatment in 67.0% of patients, and the most frequent ICI used was nivolumab plus ipilimumab (42.9%), followed by PD-1 inhibitor monotherapy (29.7%). The table shows results of multivariable analyses adjusting for mRCC epithelial histology, IMDC risk group, and number of prior treatments. Patients who underwent a delayed or upfront CN had longer OS and time on ICI therapy than those without a nephrectomy. Table: 678P

Nephrectomy status Median time on ICI (months) HR (95% CI) P value Median OS from ICI initiation (months) HR (95% CI) P value
No nephrectomy (n=29) 5.1 - - 14.0 - -
Cytoreductive nephrectomy (n=62) 7.7 0.59 (0.35-0.99) 0.046 29.0 0.54 (0.29-0.99) 0.048

Conclusions

CN was independently associated with improved outcomes compared to not receiving a nephrectomy in patients with S/R RCC, with the strongest evidence found for time on ICI and weaker evidence for OS benefit. This hypothesis-generating study suggests that CN should be considered in select patients with S/R RCC who respond to ICI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

P. Msaouel: Financial Interests, Personal, Advisory Board: Mirati Therapeutics; Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Board: Exelixis; Financial Interests, Personal, Invited Speaker, Non-branded educational talks: Exelixis; Financial Interests, Personal, Invited Speaker, Non-branded educational talks: Pfizer; Financial Interests, Institutional, Funding: Takeda; Financial Interests, Institutional, Funding: Bristol-Myers Squibb; Financial Interests, Institutional, Funding: Mirati Therapeutics; Financial Interests, Institutional, Funding: Gateway for Cancer Research. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.